Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Opinion on Investigational Drugs (2021) Vol. 30, Iss. 4, pp. 343-350
Closed Access | Times Cited: 101

Showing 1-25 of 101 citing articles:

Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond
Alessandro Rizzo, Angela Dalia Ricci
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 6, pp. 549-555
Closed Access | Times Cited: 111
Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Alessandro Rizzo, Antonio Cusmai, Gennaro Gadaleta‐Caldarola, et al.
Expert Review of Gastroenterology & Hepatology (2022) Vol. 16, Iss. 4, pp. 333-339
Closed Access | Times Cited: 79
PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
Adil Parvez, Furqan Choudhary, Priyal Mudgal, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 63
PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?
Alessandro Rizzo, Angela Dalia Ricci
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 4, pp. 415-423
Closed Access | Times Cited: 91
Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review
Alessandro Rizzo, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100354-100354
Open Access | Times Cited: 88
First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges
Alessandro Rizzo, Angela Dalia Ricci, Gennaro Gadaleta‐Caldarola, et al.
Expert Review of Gastroenterology & Hepatology (2021) Vol. 15, Iss. 11, pp. 1245-1251
Closed Access | Times Cited: 81
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects
Alessandro Rizzo, Angela Dalia Ricci, Laura Lanotte, et al.
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 6, pp. 557-565
Closed Access | Times Cited: 80
Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Journal of Personalized Medicine (2022) Vol. 12, Iss. 11, pp. 1788-1788
Open Access | Times Cited: 57
Enhancement of CAR‐T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins
Yidan Qiao, Jie Chen, Xuemei Wang, et al.
Cancer Communications (2023) Vol. 43, Iss. 7, pp. 788-807
Open Access | Times Cited: 25
Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application
Xiaoxue Ren, Mingle Huang, Weixiang Weng, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 11, pp. 101277-101277
Open Access | Times Cited: 22
Immune and inflammatory mechanisms and therapeutic targets of gout: An update
Wenji Liu, Jie Peng, Yixin Wu, et al.
International Immunopharmacology (2023) Vol. 121, pp. 110466-110466
Closed Access | Times Cited: 16
Immunotherapy and targeted therapy for cholangiocarcinoma: Artificial intelligence research in imaging
Jiong Liu, Jian Shu
Critical Reviews in Oncology/Hematology (2024) Vol. 194, pp. 104235-104235
Closed Access | Times Cited: 5
Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer—Current Treatment Options and Future Perspectives
Evangelos Koustas, Eleni-Myrto Trifylli, Panagiotis Sarantis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6664-6664
Open Access | Times Cited: 22
Emerging trends and thematic evolution of immunotherapy for glioma based on the top 100 cited articles
Yan Zhou, Min Liu, Xing Huang, et al.
Frontiers in Oncology (2024) Vol. 13
Open Access | Times Cited: 4
Sex disparity in clinical characteristics and long-term prognosis after liver resection for patients with intrahepatic cholangiocarcinoma: A propensity score matching analysis
Yiran Zou, Xin‐Fei Xu, Tanyang Wu, et al.
Heliyon (2024) Vol. 10, Iss. 9, pp. e29910-e29910
Open Access | Times Cited: 4
Management of intrahepatic cholangiocarcinoma: a review for clinicians
Matteo Colangelo, Marcello Di Martino, Michela Anna Polidoro, et al.
Gastroenterology report (2025) Vol. 13
Open Access
Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy
Hongli Wang, Zhi‐Gang Wang, Shu‐Lin Liu
Molecules (2022) Vol. 27, Iss. 17, pp. 5607-5607
Open Access | Times Cited: 21
Feasibility and tolerability of sintilimab plus anlotinib as the second‐line therapy for patients with advanced biliary tract cancers: An open‐label, single‐arm, phase II clinical trial
Shuiling Jin, Ruihua Zhao, Chuang Zhou, et al.
International Journal of Cancer (2022) Vol. 152, Iss. 8, pp. 1648-1658
Closed Access | Times Cited: 20
MUC1 induces the accumulation of Foxp3+ Treg cells in the tumor microenvironment to promote the growth and metastasis of cholangiocarcinoma through the EGFR/PI3K/Akt signaling pathway
Guofeng Zhang, Zheng Ge, Haipeng Zhang, et al.
International Immunopharmacology (2023) Vol. 118, pp. 110091-110091
Closed Access | Times Cited: 12
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100356-100356
Open Access | Times Cited: 25
Prognostic factors for resected cases with gallbladder carcinoma: A systematic review and meta-analysis
Tian‐Run Lv, Jun-Ke Wang, Fu‐Yu Li, et al.
International Journal of Surgery (2024)
Open Access | Times Cited: 3
Clinical epidemiology of gallbladder cancer in North-Central India and association of immunological markers, NLR, MLR and PLR in the diagnostic/prognostic prediction of GBC
Jyotsna Singh, Durgesh Shukla, Sanjiv Gupta, et al.
Cancer Treatment and Research Communications (2021) Vol. 28, pp. 100431-100431
Open Access | Times Cited: 21
Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy
Min Deng, Shaohua Li, Qiaoxuan Wang, et al.
Annals of Medicine (2022) Vol. 54, Iss. 1, pp. 803-811
Open Access | Times Cited: 15
Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review
Wei Zhang, Luo Chu, Zun-Yi Zhang, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 8
First-line PD-1 inhibitors combination therapy for patients with advanced cholangiocarcinoma: A retrospective real-world study
Ziqi Ye, Y. Zhang, Jie Chen, et al.
International Immunopharmacology (2023) Vol. 120, pp. 110344-110344
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top